Patricia Carr Sells 1,117 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CAO Patricia Carr sold 1,117 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $190.91, for a total transaction of $213,246.47. Following the completion of the sale, the chief accounting officer directly owned 9,235 shares of the company’s stock, valued at approximately $1,763,053.85. This trade represents a 10.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Patricia Carr also recently made the following trade(s):

• On Thursday, February 26th, Patricia Carr sold 1,253 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $194.11, for a total value of $243,219.83.
• On Friday, December 5th, Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $171.20, for a total value of $797,792.00.

Jazz Pharmaceuticals Trading Down 2.0%

JAZZ opened at $186.67 on Wednesday. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00. The business’s 50 day moving average is $170.40 and its two-hundred day moving average is $152.93. The firm has a market cap of $11.49 billion, a price-to-earnings ratio of -31.27, a price-to-earnings-growth ratio of 0.38 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the firm posted $6.51 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Kennedy Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth about $1,100,000. Essex Investment Management Co. LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $2,697,000. Wedge Capital Management L L P NC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $27,834,000. Sequoia Financial Advisors LLC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $605,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 8.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can raise visibility and institutional interest and is a modest positive for sentiment. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: Management presented at the TD Cowen Health Care Conference; the transcript provides updates on strategy and pipeline but did not announce major new approvals or guidance changes likely to move the stock immediately. Conference Transcript
• Neutral Sentiment: A Zacks note discusses Jazz’s reliance on international sales and how revenue mix could affect analyst forecasts — useful for modeling risk/benefit but not an immediate catalyst unless estimates are revised. Zacks International Sales Analysis
• Negative Sentiment: Large insider sale by EVP Neena M. Patil: 55,600 shares sold (~$10.65M at ~ $191.56/share), representing roughly a 49% reduction in her stake — a sizable single insider liquidation that can pressure sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); these are meaningful percentage reductions and add to downward pressure. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing
• Negative Sentiment: CAO Patricia Carr executed multiple sales (1,253 and 1,117 shares recently), a smaller but repeated reduction that contributes to the pattern of insider selling. Patricia Carr Insider Trades

Analyst Ratings Changes

A number of analysts have weighed in on JAZZ shares. Barclays initiated coverage on Jazz Pharmaceuticals in a research report on Friday, February 27th. They set an “overweight” rating and a $224.00 price objective for the company. Royal Bank Of Canada lifted their price objective on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $214.57.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.